nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—submandibular gland—pharynx cancer	0.0507	0.0858	CbGeAlD
Nilotinib—CA6—saliva—pharynx cancer	0.0182	0.0309	CbGeAlD
Nilotinib—CA6—ear—pharynx cancer	0.0167	0.0283	CbGeAlD
Nilotinib—CA3—ear—pharynx cancer	0.0158	0.0268	CbGeAlD
Nilotinib—EPHA4—tongue—pharynx cancer	0.00983	0.0167	CbGeAlD
Nilotinib—MAPK8—mouth—pharynx cancer	0.0096	0.0163	CbGeAlD
Nilotinib—MAPK8—neck—pharynx cancer	0.00821	0.0139	CbGeAlD
Nilotinib—EPHB2—brainstem—pharynx cancer	0.00785	0.0133	CbGeAlD
Nilotinib—CA6—mouth—pharynx cancer	0.0069	0.0117	CbGeAlD
Nilotinib—EPHA4—mouth—pharynx cancer	0.00661	0.0112	CbGeAlD
Nilotinib—CA3—mouth—pharynx cancer	0.00653	0.0111	CbGeAlD
Nilotinib—MAPK8—brainstem—pharynx cancer	0.00627	0.0106	CbGeAlD
Nilotinib—MAPK14—mouth—pharynx cancer	0.0061	0.0103	CbGeAlD
Nilotinib—FRK—lymphoid tissue—pharynx cancer	0.00564	0.00956	CbGeAlD
Nilotinib—MAPK8—epithelium—pharynx cancer	0.00559	0.00946	CbGeAlD
Nilotinib—CDC42BPB—trachea—pharynx cancer	0.00546	0.00925	CbGeAlD
Nilotinib—BLK—lymphoid tissue—pharynx cancer	0.00544	0.00922	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—pharynx cancer	0.00538	0.00912	CbGeAlD
Nilotinib—EPHB3—saliva-secreting gland—pharynx cancer	0.00528	0.00895	CbGeAlD
Nilotinib—MAPK14—neck—pharynx cancer	0.00521	0.00883	CbGeAlD
Nilotinib—EPHB3—brainstem—pharynx cancer	0.00517	0.00876	CbGeAlD
Nilotinib—TIE1—epithelium—pharynx cancer	0.00484	0.0082	CbGeAlD
Nilotinib—CA6—parotid gland—pharynx cancer	0.0048	0.00814	CbGeAlD
Nilotinib—CA6—saliva-secreting gland—pharynx cancer	0.0046	0.00779	CbGeAlD
Nilotinib—CA3—parotid gland—pharynx cancer	0.00455	0.00771	CbGeAlD
Nilotinib—EPHB2—head—pharynx cancer	0.00434	0.00735	CbGeAlD
Nilotinib—EPHA4—brainstem—pharynx cancer	0.00432	0.00732	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—pharynx cancer	0.00431	0.00731	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—pharynx cancer	0.0043	0.00729	CbGeAlD
Nilotinib—EPHA8—head—pharynx cancer	0.00416	0.00704	CbGeAlD
Nilotinib—EPHB3—trachea—pharynx cancer	0.00407	0.0069	CbGeAlD
Nilotinib—EPHB4—parotid gland—pharynx cancer	0.00403	0.00682	CbGeAlD
Nilotinib—KIT—mouth—pharynx cancer	0.00401	0.00679	CbGeAlD
Nilotinib—MAPK14—brainstem—pharynx cancer	0.00398	0.00675	CbGeAlD
Nilotinib—LYN—lymphoid tissue—pharynx cancer	0.00397	0.00673	CbGeAlD
Nilotinib—EPHA2—parotid gland—pharynx cancer	0.00395	0.00669	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—pharynx cancer	0.00391	0.00662	CbGeAlD
Nilotinib—MAPK8—spinal cord—pharynx cancer	0.0039	0.00661	CbGeAlD
Nilotinib—MAPK11—head—pharynx cancer	0.00387	0.00655	CbGeAlD
Nilotinib—EPHB4—saliva-secreting gland—pharynx cancer	0.00386	0.00653	CbGeAlD
Nilotinib—CDC42BPB—head—pharynx cancer	0.00383	0.00649	CbGeAlD
Nilotinib—EPHA2—saliva-secreting gland—pharynx cancer	0.00378	0.00641	CbGeAlD
Nilotinib—HCK—trachea—pharynx cancer	0.00374	0.00634	CbGeAlD
Nilotinib—EPHB6—parotid gland—pharynx cancer	0.00368	0.00624	CbGeAlD
Nilotinib—CA7—trachea—pharynx cancer	0.00366	0.00621	CbGeAlD
Nilotinib—EPHA3—head—pharynx cancer	0.00363	0.00616	CbGeAlD
Nilotinib—MAPK14—epithelium—pharynx cancer	0.00355	0.00601	CbGeAlD
Nilotinib—EPHB6—saliva-secreting gland—pharynx cancer	0.00353	0.00597	CbGeAlD
Nilotinib—MAPK8—head—pharynx cancer	0.00347	0.00587	CbGeAlD
Nilotinib—EPHA6—head—pharynx cancer	0.00347	0.00587	CbGeAlD
Nilotinib—KIT—neck—pharynx cancer	0.00343	0.0058	CbGeAlD
Nilotinib—EPHA4—trachea—pharynx cancer	0.0034	0.00576	CbGeAlD
Nilotinib—EPHB4—epithelium—pharynx cancer	0.00336	0.0057	CbGeAlD
Nilotinib—PDGFRB—neck—pharynx cancer	0.00335	0.00567	CbGeAlD
Nilotinib—EPHA2—epithelium—pharynx cancer	0.0033	0.00559	CbGeAlD
Nilotinib—HCK—lymphoid tissue—pharynx cancer	0.00326	0.00552	CbGeAlD
Nilotinib—TEK—epithelium—pharynx cancer	0.00322	0.00545	CbGeAlD
Nilotinib—EPHB3—spinal cord—pharynx cancer	0.00322	0.00545	CbGeAlD
Nilotinib—LYN—head—pharynx cancer	0.0032	0.00542	CbGeAlD
Nilotinib—MAP2K5—parotid gland—pharynx cancer	0.00315	0.00533	CbGeAlD
Nilotinib—LCK—trachea—pharynx cancer	0.00312	0.00529	CbGeAlD
Nilotinib—BLK—lymph node—pharynx cancer	0.00307	0.0052	CbGeAlD
Nilotinib—MAP2K5—saliva-secreting gland—pharynx cancer	0.00302	0.00511	CbGeAlD
Nilotinib—TIE1—head—pharynx cancer	0.00301	0.00509	CbGeAlD
Nilotinib—EPHB4—trachea—pharynx cancer	0.00297	0.00504	CbGeAlD
Nilotinib—HCK—spinal cord—pharynx cancer	0.00296	0.00501	CbGeAlD
Nilotinib—MAP2K5—brainstem—pharynx cancer	0.00295	0.005	CbGeAlD
Nilotinib—EPHA2—trachea—pharynx cancer	0.00292	0.00494	CbGeAlD
Nilotinib—EPHB3—head—pharynx cancer	0.00286	0.00484	CbGeAlD
Nilotinib—KIT—parotid gland—pharynx cancer	0.00279	0.00473	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—pharynx cancer	0.00273	0.00463	CbGeAlD
Nilotinib—PDGFRB—parotid gland—pharynx cancer	0.00273	0.00462	CbGeAlD
Nilotinib—FGR—lymphoid tissue—pharynx cancer	0.00272	0.00461	CbGeAlD
Nilotinib—EPHB6—trachea—pharynx cancer	0.00272	0.00461	CbGeAlD
Nilotinib—MAPK11—lymph node—pharynx cancer	0.00271	0.00458	CbGeAlD
Nilotinib—CDC42BPB—lymph node—pharynx cancer	0.00268	0.00455	CbGeAlD
Nilotinib—KIT—saliva-secreting gland—pharynx cancer	0.00267	0.00453	CbGeAlD
Nilotinib—HCK—head—pharynx cancer	0.00263	0.00445	CbGeAlD
Nilotinib—KIT—brainstem—pharynx cancer	0.00262	0.00443	CbGeAlD
Nilotinib—PDGFRB—saliva-secreting gland—pharynx cancer	0.00261	0.00442	CbGeAlD
Nilotinib—PDGFRA—trachea—pharynx cancer	0.00258	0.00437	CbGeAlD
Nilotinib—EPHA3—lymph node—pharynx cancer	0.00254	0.00431	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—pharynx cancer	0.00254	0.0043	CbGeAlD
Nilotinib—CA6—head—pharynx cancer	0.00249	0.00422	CbGeAlD
Nilotinib—TEK—lymphoid tissue—pharynx cancer	0.00248	0.0042	CbGeAlD
Nilotinib—MAPK14—spinal cord—pharynx cancer	0.00248	0.0042	CbGeAlD
Nilotinib—CA4—neck—pharynx cancer	0.00245	0.00415	CbGeAlD
Nilotinib—ABL1—parotid gland—pharynx cancer	0.00243	0.00411	CbGeAlD
Nilotinib—MAPK8—lymph node—pharynx cancer	0.00243	0.00411	CbGeAlD
Nilotinib—CA14—spinal cord—pharynx cancer	0.00241	0.00408	CbGeAlD
Nilotinib—EPHA4—head—pharynx cancer	0.00239	0.00404	CbGeAlD
Nilotinib—CA12—trachea—pharynx cancer	0.00238	0.00403	CbGeAlD
Nilotinib—CA2—mouth—pharynx cancer	0.00238	0.00402	CbGeAlD
Nilotinib—CA3—head—pharynx cancer	0.00236	0.004	CbGeAlD
Nilotinib—EPHB4—spinal cord—pharynx cancer	0.00235	0.00398	CbGeAlD
Nilotinib—KIT—epithelium—pharynx cancer	0.00233	0.00395	CbGeAlD
Nilotinib—ABL1—saliva-secreting gland—pharynx cancer	0.00233	0.00394	CbGeAlD
Nilotinib—MAP2K5—trachea—pharynx cancer	0.00233	0.00394	CbGeAlD
Nilotinib—ABL1—brainstem—pharynx cancer	0.00228	0.00386	CbGeAlD
Nilotinib—PDGFRB—epithelium—pharynx cancer	0.00228	0.00386	CbGeAlD
Nilotinib—CSF1R—trachea—pharynx cancer	0.00227	0.00385	CbGeAlD
Nilotinib—TEK—spinal cord—pharynx cancer	0.00225	0.00381	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—pharynx cancer	0.00225	0.0038	CbGeAlD
Nilotinib—MAP4K1—lymph node—pharynx cancer	0.00221	0.00374	CbGeAlD
Nilotinib—MAPK14—head—pharynx cancer	0.0022	0.00373	CbGeAlD
Nilotinib—FGR—head—pharynx cancer	0.00219	0.00371	CbGeAlD
Nilotinib—EPHB6—spinal cord—pharynx cancer	0.00215	0.00364	CbGeAlD
Nilotinib—TIE1—lymph node—pharynx cancer	0.0021	0.00357	CbGeAlD
Nilotinib—KIT—trachea—pharynx cancer	0.00206	0.00349	CbGeAlD
Nilotinib—EPHA2—head—pharynx cancer	0.00205	0.00347	CbGeAlD
Nilotinib—PDGFRA—spinal cord—pharynx cancer	0.00204	0.00345	CbGeAlD
Nilotinib—CA2—neck—pharynx cancer	0.00203	0.00344	CbGeAlD
Nilotinib—BRAF—lymph node—pharynx cancer	0.00202	0.00342	CbGeAlD
Nilotinib—PDGFRB—trachea—pharynx cancer	0.00201	0.00341	CbGeAlD
Nilotinib—EPHB3—lymph node—pharynx cancer	0.002	0.00339	CbGeAlD
Nilotinib—TEK—head—pharynx cancer	0.002	0.00338	CbGeAlD
Nilotinib—CA4—parotid gland—pharynx cancer	0.00199	0.00338	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—pharynx cancer	0.00198	0.00335	CbGeAlD
Nilotinib—CA4—saliva-secreting gland—pharynx cancer	0.00191	0.00324	CbGeAlD
Nilotinib—EPHB6—head—pharynx cancer	0.00191	0.00323	CbGeAlD
Nilotinib—CA4—brainstem—pharynx cancer	0.00187	0.00317	CbGeAlD
Nilotinib—HCK—lymph node—pharynx cancer	0.00184	0.00312	CbGeAlD
Nilotinib—MAP2K5—spinal cord—pharynx cancer	0.00184	0.00311	CbGeAlD
Nilotinib—ABL2—lymph node—pharynx cancer	0.00183	0.0031	CbGeAlD
Nilotinib—PDGFRA—head—pharynx cancer	0.00181	0.00307	CbGeAlD
Nilotinib—KIT—lymphoid tissue—pharynx cancer	0.0018	0.00304	CbGeAlD
Nilotinib—ABL1—trachea—pharynx cancer	0.00179	0.00304	CbGeAlD
Nilotinib—CSF1R—spinal cord—pharynx cancer	0.00179	0.00304	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—pharynx cancer	0.00175	0.00297	CbGeAlD
Nilotinib—EPHA4—lymph node—pharynx cancer	0.00167	0.00283	CbGeAlD
Nilotinib—CA12—head—pharynx cancer	0.00167	0.00283	CbGeAlD
Nilotinib—CA2—parotid gland—pharynx cancer	0.00165	0.0028	CbGeAlD
Nilotinib—CA3—lymph node—pharynx cancer	0.00165	0.0028	CbGeAlD
Nilotinib—CA1—lymphoid tissue—pharynx cancer	0.00164	0.00278	CbGeAlD
Nilotinib—MAP2K5—head—pharynx cancer	0.00163	0.00277	CbGeAlD
Nilotinib—KIT—spinal cord—pharynx cancer	0.00163	0.00276	CbGeAlD
Nilotinib—CSF1R—head—pharynx cancer	0.00159	0.0027	CbGeAlD
Nilotinib—PDGFRB—spinal cord—pharynx cancer	0.00159	0.00269	CbGeAlD
Nilotinib—CA2—saliva-secreting gland—pharynx cancer	0.00158	0.00268	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—pharynx cancer	0.00156	0.00265	CbGeAlD
Nilotinib—CA2—brainstem—pharynx cancer	0.00155	0.00263	CbGeAlD
Nilotinib—MAPK14—lymph node—pharynx cancer	0.00154	0.00261	CbGeAlD
Nilotinib—FGR—lymph node—pharynx cancer	0.00154	0.0026	CbGeAlD
Nilotinib—LCK—lymph node—pharynx cancer	0.00154	0.0026	CbGeAlD
Nilotinib—ABCG2—parotid gland—pharynx cancer	0.00153	0.00259	CbGeAlD
Nilotinib—CA1—spinal cord—pharynx cancer	0.00149	0.00252	CbGeAlD
Nilotinib—CA4—trachea—pharynx cancer	0.00147	0.0025	CbGeAlD
Nilotinib—ABCG2—saliva-secreting gland—pharynx cancer	0.00147	0.00248	CbGeAlD
Nilotinib—EPHB4—lymph node—pharynx cancer	0.00146	0.00248	CbGeAlD
Nilotinib—KIT—head—pharynx cancer	0.00145	0.00245	CbGeAlD
Nilotinib—EPHA2—lymph node—pharynx cancer	0.00143	0.00243	CbGeAlD
Nilotinib—ABL1—spinal cord—pharynx cancer	0.00142	0.0024	CbGeAlD
Nilotinib—PDGFRB—head—pharynx cancer	0.00141	0.00239	CbGeAlD
Nilotinib—TEK—lymph node—pharynx cancer	0.0014	0.00237	CbGeAlD
Nilotinib—CA2—epithelium—pharynx cancer	0.00138	0.00234	CbGeAlD
Nilotinib—EPHB6—lymph node—pharynx cancer	0.00134	0.00226	CbGeAlD
Nilotinib—CA1—head—pharynx cancer	0.00132	0.00224	CbGeAlD
Nilotinib—PDGFRA—lymph node—pharynx cancer	0.00127	0.00215	CbGeAlD
Nilotinib—ABL1—head—pharynx cancer	0.00126	0.00213	CbGeAlD
Nilotinib—CA2—trachea—pharynx cancer	0.00122	0.00207	CbGeAlD
Nilotinib—CA4—spinal cord—pharynx cancer	0.00116	0.00197	CbGeAlD
Nilotinib—MAP2K5—lymph node—pharynx cancer	0.00114	0.00194	CbGeAlD
Nilotinib—CSF1R—lymph node—pharynx cancer	0.00112	0.00189	CbGeAlD
Nilotinib—CA2—lymphoid tissue—pharynx cancer	0.00106	0.0018	CbGeAlD
Nilotinib—CA4—head—pharynx cancer	0.00103	0.00175	CbGeAlD
Nilotinib—KIT—lymph node—pharynx cancer	0.00101	0.00172	CbGeAlD
Nilotinib—PDGFRB—lymph node—pharynx cancer	0.000989	0.00168	CbGeAlD
Nilotinib—CYP2D6—brainstem—pharynx cancer	0.000985	0.00167	CbGeAlD
Nilotinib—CA2—spinal cord—pharynx cancer	0.000965	0.00163	CbGeAlD
Nilotinib—CA1—lymph node—pharynx cancer	0.000927	0.00157	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—pharynx cancer	0.000909	0.00154	CbGeAlD
Nilotinib—ABCG2—spinal cord—pharynx cancer	0.000894	0.00151	CbGeAlD
Nilotinib—ABL1—lymph node—pharynx cancer	0.000882	0.00149	CbGeAlD
Nilotinib—CA2—head—pharynx cancer	0.000858	0.00145	CbGeAlD
Nilotinib—CYP2B6—head—pharynx cancer	0.000733	0.00124	CbGeAlD
Nilotinib—CA4—lymph node—pharynx cancer	0.000724	0.00123	CbGeAlD
Nilotinib—ABCB1—epithelium—pharynx cancer	0.000631	0.00107	CbGeAlD
Nilotinib—CA2—lymph node—pharynx cancer	0.0006	0.00102	CbGeAlD
Nilotinib—ABCB1—trachea—pharynx cancer	0.000558	0.000945	CbGeAlD
Nilotinib—ABCG2—lymph node—pharynx cancer	0.000556	0.000942	CbGeAlD
Nilotinib—CYP2D6—head—pharynx cancer	0.000544	0.000922	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—pharynx cancer	0.000486	0.000823	CbGeAlD
Nilotinib—ABCB1—spinal cord—pharynx cancer	0.000441	0.000746	CbGeAlD
Nilotinib—ABCB1—head—pharynx cancer	0.000392	0.000663	CbGeAlD
Nilotinib—PDGFRA—Downstream signal transduction—EGFR—pharynx cancer	0.000328	0.000801	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR—EGFR—pharynx cancer	0.000327	0.000798	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by ERBB2—EGFR—pharynx cancer	0.000325	0.000794	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CNDP2—pharynx cancer	0.000325	0.000793	CbGpPWpGaD
Nilotinib—MAPK14—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.000324	0.000792	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 signaling—EGFR—pharynx cancer	0.000324	0.00079	CbGpPWpGaD
Nilotinib—LYN—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000322	0.000786	CbGpPWpGaD
Nilotinib—KIT—DAP12 interactions—EGFR—pharynx cancer	0.000322	0.000785	CbGpPWpGaD
Nilotinib—KIT—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000322	0.000785	CbGpPWpGaD
Nilotinib—KIT—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000322	0.000785	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—EGFR—pharynx cancer	0.000321	0.000784	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—B4GALT5—pharynx cancer	0.000321	0.000783	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.00032	0.000782	CbGpPWpGaD
Nilotinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000319	0.000778	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR—EGFR—pharynx cancer	0.000319	0.000778	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—EGFR—pharynx cancer	0.000318	0.000775	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—EGFR—pharynx cancer	0.000318	0.000775	CbGpPWpGaD
Nilotinib—KIT—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000316	0.000771	CbGpPWpGaD
Nilotinib—MAPK11—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000316	0.000771	CbGpPWpGaD
Nilotinib—PDGFRB—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.000315	0.000768	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000315	0.000768	CbGpPWpGaD
Nilotinib—KIT—Signaling by PDGF—EGFR—pharynx cancer	0.000314	0.000768	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD79A—pharynx cancer	0.000314	0.000767	CbGpPWpGaD
Nilotinib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000313	0.000764	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD79A—pharynx cancer	0.000311	0.000759	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD79A—pharynx cancer	0.000311	0.000759	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD79A—pharynx cancer	0.00031	0.000756	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB4—EGFR—pharynx cancer	0.00031	0.000756	CbGpPWpGaD
Nilotinib—BRAF—MAPK Signaling Pathway—TP53—pharynx cancer	0.000309	0.000755	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—EGFR—pharynx cancer	0.000308	0.000751	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD79A—pharynx cancer	0.000307	0.000751	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000305	0.000745	CbGpPWpGaD
Nilotinib—MAPK8—Signaling by NGF—EGFR—pharynx cancer	0.000305	0.000744	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000304	0.000743	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 interactions—EGFR—pharynx cancer	0.000304	0.000743	CbGpPWpGaD
Nilotinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000304	0.000743	CbGpPWpGaD
Nilotinib—ABL1—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.000303	0.000741	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR—EGFR—pharynx cancer	0.000302	0.000736	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000299	0.00073	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—EGFR—pharynx cancer	0.000299	0.000729	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by PDGF—EGFR—pharynx cancer	0.000298	0.000727	CbGpPWpGaD
Nilotinib—KIT—B Cell Activation—EGFR—pharynx cancer	0.000298	0.000726	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signal transduction—EGFR—pharynx cancer	0.000296	0.000722	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR—EGFR—pharynx cancer	0.000294	0.000718	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ADH7—pharynx cancer	0.000294	0.000717	CbGpPWpGaD
Nilotinib—MAPK14—Oxidative Stress Induced Senescence—TP53—pharynx cancer	0.000294	0.000717	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by ERBB2—EGFR—pharynx cancer	0.000293	0.000715	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 signaling—EGFR—pharynx cancer	0.000291	0.000711	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling by NGF—EGFR—pharynx cancer	0.00029	0.000708	CbGpPWpGaD
Nilotinib—MAPK11—Cellular Senescence—TP53—pharynx cancer	0.000288	0.000702	CbGpPWpGaD
Nilotinib—PDGFRA—Focal Adhesion—EGFR—pharynx cancer	0.000288	0.000702	CbGpPWpGaD
Nilotinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000287	0.000701	CbGpPWpGaD
Nilotinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000287	0.0007	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000286	0.000699	CbGpPWpGaD
Nilotinib—PDGFRB—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000286	0.000698	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CDH1—pharynx cancer	0.000286	0.000697	CbGpPWpGaD
Nilotinib—KIT—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000285	0.000695	CbGpPWpGaD
Nilotinib—PDGFRA—B Cell Activation—EGFR—pharynx cancer	0.000282	0.000688	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—EGFR—pharynx cancer	0.000281	0.000685	CbGpPWpGaD
Nilotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—pharynx cancer	0.000277	0.000676	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CNDP2—pharynx cancer	0.000276	0.000673	CbGpPWpGaD
Nilotinib—ABCB1—lymph node—pharynx cancer	0.000274	0.000465	CbGeAlD
Nilotinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000274	0.000669	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000274	0.000669	CbGpPWpGaD
Nilotinib—PDGFRB—DAP12 interactions—EGFR—pharynx cancer	0.000274	0.000669	CbGpPWpGaD
Nilotinib—MAPK14—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000273	0.000667	CbGpPWpGaD
Nilotinib—MAPK8—Cellular responses to stress—TP53—pharynx cancer	0.000273	0.000666	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR—EGFR—pharynx cancer	0.000272	0.000663	CbGpPWpGaD
Nilotinib—MAPK14—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.00027	0.00066	CbGpPWpGaD
Nilotinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00027	0.000658	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000269	0.000657	CbGpPWpGaD
Nilotinib—LYN—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000268	0.000655	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by PDGF—EGFR—pharynx cancer	0.000268	0.000655	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000265	0.000648	CbGpPWpGaD
Nilotinib—LCK—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000264	0.000644	CbGpPWpGaD
Nilotinib—PDGFRB—Focal Adhesion—EGFR—pharynx cancer	0.000259	0.000632	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—EGFR—pharynx cancer	0.000259	0.000632	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ADH1B—pharynx cancer	0.000258	0.000629	CbGpPWpGaD
Nilotinib—LCK—Disease—B4GALT5—pharynx cancer	0.000258	0.000629	CbGpPWpGaD
Nilotinib—CA9—Cellular responses to stress—TP53—pharynx cancer	0.000257	0.000628	CbGpPWpGaD
Nilotinib—ABL1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000255	0.000622	CbGpPWpGaD
Nilotinib—PDGFRB—B Cell Activation—EGFR—pharynx cancer	0.000254	0.000619	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000253	0.000616	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD79A—pharynx cancer	0.000252	0.000615	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000251	0.000614	CbGpPWpGaD
Nilotinib—TEK—Hemostasis—TP53—pharynx cancer	0.000251	0.000612	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADH7—pharynx cancer	0.000249	0.000609	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB4—EGFR—pharynx cancer	0.000249	0.000607	CbGpPWpGaD
Nilotinib—LYN—B Cell Activation—EGFR—pharynx cancer	0.000248	0.000606	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD79A—pharynx cancer	0.000248	0.000605	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—B4GALT5—pharynx cancer	0.000246	0.000601	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—EGFR—pharynx cancer	0.000243	0.000593	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000243	0.000593	CbGpPWpGaD
Nilotinib—BRAF—Signaling by NGF—EGFR—pharynx cancer	0.000241	0.000587	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.00024	0.000587	CbGpPWpGaD
Nilotinib—PDGFRB—MAPK Signaling Pathway—TP53—pharynx cancer	0.00024	0.000586	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000239	0.000585	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—EGFR—pharynx cancer	0.000237	0.000579	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—EGFR—pharynx cancer	0.000236	0.000577	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—EGFR—pharynx cancer	0.000235	0.000574	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—EGFR—pharynx cancer	0.000234	0.000571	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000231	0.000563	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000225	0.00055	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD79A—pharynx cancer	0.000223	0.000545	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—TP53—pharynx cancer	0.000223	0.000544	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—EGFR—pharynx cancer	0.00022	0.000537	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.00022	0.000537	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—EGFR—pharynx cancer	0.00022	0.000537	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—EGFR—pharynx cancer	0.000219	0.000535	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ADH1B—pharynx cancer	0.000219	0.000534	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—EGFR—pharynx cancer	0.000218	0.000532	CbGpPWpGaD
Nilotinib—MAPK11—Cellular responses to stress—TP53—pharynx cancer	0.000217	0.000531	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000216	0.000528	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—EGFR—pharynx cancer	0.000215	0.000525	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD79A—pharynx cancer	0.000211	0.000516	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000211	0.000515	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—B4GALT5—pharynx cancer	0.000209	0.00051	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—EGFR—pharynx cancer	0.000207	0.000506	CbGpPWpGaD
Nilotinib—MAPK14—Cellular Senescence—TP53—pharynx cancer	0.000205	0.000501	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CDH1—pharynx cancer	0.000205	0.000501	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—EGFR—pharynx cancer	0.000204	0.000497	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CNDP2—pharynx cancer	0.000202	0.000493	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000201	0.000491	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000195	0.000476	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CDH1—pharynx cancer	0.000194	0.000474	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—EGFR—pharynx cancer	0.000192	0.000468	CbGpPWpGaD
Nilotinib—HCK—Immune System—CDH1—pharynx cancer	0.000191	0.000467	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD79A—pharynx cancer	0.00019	0.000465	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—EGFR—pharynx cancer	0.000187	0.000456	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD79A—pharynx cancer	0.000186	0.000455	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD79A—pharynx cancer	0.000186	0.000453	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADH7—pharynx cancer	0.000183	0.000446	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD79A—pharynx cancer	0.000177	0.000432	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CDH1—pharynx cancer	0.000175	0.000427	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—EGFR—pharynx cancer	0.000174	0.000424	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—EGFR—pharynx cancer	0.000173	0.000423	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—EGFR—pharynx cancer	0.000173	0.000423	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CDH1—pharynx cancer	0.000173	0.000423	CbGpPWpGaD
Nilotinib—BLK—Immune System—CDH1—pharynx cancer	0.000173	0.000423	CbGpPWpGaD
Nilotinib—FGR—Immune System—CDH1—pharynx cancer	0.000173	0.000421	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CDH1—pharynx cancer	0.000171	0.000418	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CNDP2—pharynx cancer	0.000171	0.000418	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—EGFR—pharynx cancer	0.000167	0.000408	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—EGFR—pharynx cancer	0.000166	0.000404	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—EGFR—pharynx cancer	0.000165	0.000402	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—pharynx cancer	0.000162	0.000395	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ADH1B—pharynx cancer	0.00016	0.000391	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—EGFR—pharynx cancer	0.000157	0.000383	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—pharynx cancer	0.000155	0.000379	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADH7—pharynx cancer	0.000155	0.000378	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—B4GALT5—pharynx cancer	0.000153	0.000374	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD79A—pharynx cancer	0.000153	0.000373	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—EGFR—pharynx cancer	0.00015	0.000366	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000149	0.000364	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CNDP2—pharynx cancer	0.00014	0.000343	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CDH1—pharynx cancer	0.00014	0.000343	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CNDP2—pharynx cancer	0.000139	0.00034	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—EGFR—pharynx cancer	0.000139	0.000338	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000138	0.000337	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CDH1—pharynx cancer	0.000138	0.000337	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADH1B—pharynx cancer	0.000136	0.000331	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADH7—pharynx cancer	0.000135	0.000329	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—B4GALT5—pharynx cancer	0.00013	0.000317	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADH7—pharynx cancer	0.000127	0.00031	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADH7—pharynx cancer	0.000126	0.000307	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—pharynx cancer	0.000125	0.000305	CbGpPWpGaD
Nilotinib—KIT—Immune System—CDH1—pharynx cancer	0.000124	0.000304	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—pharynx cancer	0.00012	0.000293	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—pharynx cancer	0.000118	0.000289	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADH1B—pharynx cancer	0.000118	0.000289	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—pharynx cancer	0.000118	0.000288	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CDH1—pharynx cancer	0.000118	0.000288	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—pharynx cancer	0.000118	0.000287	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—pharynx cancer	0.000114	0.000277	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—B4GALT5—pharynx cancer	0.000113	0.000276	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—pharynx cancer	0.000112	0.000273	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—pharynx cancer	0.000112	0.000273	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADH1B—pharynx cancer	0.000111	0.000272	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADH1B—pharynx cancer	0.00011	0.00027	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000108	0.000265	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—pharynx cancer	0.000107	0.00026	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—B4GALT5—pharynx cancer	0.000106	0.00026	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDH1—pharynx cancer	0.000106	0.000259	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—B4GALT5—pharynx cancer	0.000106	0.000258	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—pharynx cancer	0.000104	0.000255	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDH1—pharynx cancer	0.000104	0.000254	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—pharynx cancer	0.000104	0.000253	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDH1—pharynx cancer	0.000103	0.000252	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—pharynx cancer	0.000103	0.000252	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—pharynx cancer	0.000102	0.00025	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—pharynx cancer	0.000101	0.000247	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—pharynx cancer	0.000101	0.000247	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—pharynx cancer	0.000101	0.000246	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—pharynx cancer	0.0001	0.000245	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—pharynx cancer	9.89e-05	0.000241	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDH1—pharynx cancer	9.85e-05	0.00024	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—pharynx cancer	9.73e-05	0.000237	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—pharynx cancer	9.68e-05	0.000236	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—pharynx cancer	9.22e-05	0.000225	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	9.18e-05	0.000224	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	9.1e-05	0.000222	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—pharynx cancer	8.55e-05	0.000209	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDH1—pharynx cancer	8.51e-05	0.000208	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCND1—pharynx cancer	8.35e-05	0.000204	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADH7—pharynx cancer	8.31e-05	0.000203	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—pharynx cancer	8.21e-05	0.0002	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—pharynx cancer	8.07e-05	0.000197	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—pharynx cancer	7.97e-05	0.000195	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCND1—pharynx cancer	7.94e-05	0.000194	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—pharynx cancer	7.38e-05	0.00018	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	7.28e-05	0.000178	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—pharynx cancer	7.28e-05	0.000178	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	6.96e-05	0.00017	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—pharynx cancer	6.89e-05	0.000168	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—pharynx cancer	6.72e-05	0.000164	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—pharynx cancer	6.65e-05	0.000162	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—pharynx cancer	6.59e-05	0.000161	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—pharynx cancer	6.55e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—pharynx cancer	6.36e-05	0.000155	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—pharynx cancer	6.23e-05	0.000152	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—pharynx cancer	6.21e-05	0.000151	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—pharynx cancer	6.08e-05	0.000148	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—pharynx cancer	6.05e-05	0.000148	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—pharynx cancer	6e-05	0.000146	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—pharynx cancer	5.76e-05	0.000141	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—pharynx cancer	5.73e-05	0.00014	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—pharynx cancer	5.68e-05	0.000139	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—pharynx cancer	5.5e-05	0.000134	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—pharynx cancer	5.23e-05	0.000128	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—pharynx cancer	5.22e-05	0.000127	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—pharynx cancer	5.17e-05	0.000126	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—pharynx cancer	5.11e-05	0.000125	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—pharynx cancer	5.01e-05	0.000122	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—pharynx cancer	4.98e-05	0.000122	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—pharynx cancer	4.75e-05	0.000116	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—pharynx cancer	4.7e-05	0.000115	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—pharynx cancer	4.6e-05	0.000112	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—pharynx cancer	4.45e-05	0.000109	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—pharynx cancer	4.38e-05	0.000107	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—pharynx cancer	4.34e-05	0.000106	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—pharynx cancer	4.1e-05	0.0001	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—pharynx cancer	4.01e-05	9.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—pharynx cancer	3.95e-05	9.64e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—pharynx cancer	3.93e-05	9.59e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—pharynx cancer	3.74e-05	9.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—pharynx cancer	3.72e-05	9.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—pharynx cancer	3.37e-05	8.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—pharynx cancer	3.3e-05	8.05e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—pharynx cancer	3.22e-05	7.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—pharynx cancer	3.13e-05	7.63e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—pharynx cancer	2.7e-05	6.6e-05	CbGpPWpGaD
